New Blog Post:
First-in-Human Results for GB-0669: Durable Neutralization from an AI-Designed Antibody
Announcement:
Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma
Get the latest updates from our team on new research, thought leadership, and company news and events.